Advertisement
Advertisement

MTNB

MTNB logo

Matinas Biopharma Holdings Inc

0.5551
USD
-0.0399
-6.71%
Dec 18, 14:46 UTC -5
Open

Matinas Biopharma Holdings Inc Profile

About

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its LNC platform technology. The Company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic and orally bioavailable. The Company's lead anti-fungal product candidate, MAT2203, utilizes its proprietary lipid nano-crystal formulation technology for the safe and effective delivery of the broad-spectrum fungicidal agent, amphotericin B. Based on the positive patient clinical data reported in 2017, Matinas is preparing for a potential Phase 2 pivotal trial of MAT2203 for prevention of invasive fungal infections in patients with acute lymphoblastic leukemia.

Info & Links

CEO

Jerome D. Jabbour

Headquarters

1545 ROUTE 206 SOUTH, SUITE 302
BEDMINSTER, NJ 07921, UNITED STATES

Industry

Pharmaceuticals Major

Sector

Health Technology

Website

www.matinasbiopharma.com

Auditor

EisnerAmper LLP

Share holders

102

Employees

32

Matinas Biopharma Holdings Inc Statistics

Valuation Measures

Market Capitalization2

2.83M

Enterprise Value

-7.50M

Enterprise Value/EBITDA(ttm)

0.36

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

0.18

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-123.06%

Return on Invested Capital(ttm)

-124.53%

Return on Assets(ttm)

-94.28%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-21.04M

Net Income Available to Common(ttm)

-21.13M

Diluted EPS(ttm)

-4.85

Share Statistics

Beta (5Y Monthly)

1.67

52-Week Change

-94.97%

S&P 500 52-Week Change

26.69%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

5.09M

Dividend Yield

0.00%

Float4

4.60M

% Held by Insiders

9.60%

% Held by Institutions

11.77%

Balance Sheet

Total Cash(mrq)

10.85M

Total Cash Per Share(mrq)

2.13

Total Debt(mrq)

19.00K

Total Debt/Equity(mrq)

0.12%

Current Ratio(mrq)

5.53%

Quick Ratio(mrq)

5.53%

Book Value Per Share(mrq)

3.10

Cash Flow

Operating Cash Flow Per Share(ytd)

-2.46

Free Cash Flow(ytd)

-12.38M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement